Switch to:
Also traded in: Germany, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.31
CRH's Cash-to-Debt is ranked lower than
63% of the 703 Companies
in the Global Building Materials industry.

( Industry Median: 0.58 vs. CRH: 0.31 )
Ranked among companies with meaningful Cash-to-Debt only.
CRH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 0.4 Max: 0.87
Current: 0.31
0.13
0.87
Interest Coverage N/A
CRH's Interest Coverage is ranked lower than
67% of the 617 Companies
in the Global Building Materials industry.

( Industry Median: 14.15 vs. CRH: N/A )
Ranked among companies with meaningful Interest Coverage only.
CRH' s Interest Coverage Range Over the Past 10 Years
Min: 0.31  Med: 2.86 Max: N/A
Current: N/A
Altman Z-Score: 1.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
3-Year Revenue Growth Rate 9.50
CRH's 3-Year Revenue Growth Rate is ranked higher than
79% of the 628 Companies
in the Global Building Materials industry.

( Industry Median: 2.40 vs. CRH: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.1  Med: 6.1 Max: 24.3
Current: 9.5
-14.1
24.3
3-Year EBITDA Growth Rate 49.10
CRH's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 558 Companies
in the Global Building Materials industry.

( Industry Median: 6.80 vs. CRH: 49.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -25.1  Med: 5.6 Max: 49.1
Current: 49.1
-25.1
49.1
GuruFocus has detected 2 Warning Signs with CRH PLC $CRH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRH's 30-Y Financials

Financials (Next Earnings Date: 2017-08-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CRH Guru Trades in Q2 2016

Caxton Associates 96,600 sh (New)
Manning & Napier Advisors, Inc 99,168 sh (+19.81%)
Jim Simons Sold Out
Barrow, Hanley, Mewhinney & Strauss 27,598,237 sh (-2.93%)
Charles Brandes 1,979,818 sh (-25.76%)
» More
Q3 2016

CRH Guru Trades in Q3 2016

Steven Cohen 190,300 sh (New)
Manning & Napier Advisors, Inc 100,162 sh (+1.00%)
Caxton Associates Sold Out
Barrow, Hanley, Mewhinney & Strauss 19,168,679 sh (-30.54%)
Charles Brandes 720,639 sh (-63.60%)
» More
Q4 2016

CRH Guru Trades in Q4 2016

Jim Simons 163,000 sh (New)
Charles Brandes Sold Out
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 74,222 sh (-25.90%)
Barrow, Hanley, Mewhinney & Strauss 6,725,485 sh (-64.91%)
» More
Q1 2017

CRH Guru Trades in Q1 2017

Jim Simons 295,100 sh (+81.04%)
Manning & Napier Advisors, Inc 84,919 sh (+14.41%)
Barrow, Hanley, Mewhinney & Strauss 5,178,465 sh (-23.00%)
» More
» Details

Insider Trades

Latest Guru Trades with CRH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of CRH PLC

SymbolPriceYieldDescription
97GM.UK0.000.007% Cum.Pref Shs A
0I4D.UK0.000.005 %

Business Description

Industry: Building Materials » Building Materials    NAICS: 327310    SIC: 3241
Compare:OTCPK:CODYY, OTCPK:DKILF, OTCPK:HCMLY, NYSE:JCI, OTCPK:HDELY, OTCPK:GBERY, NYSE:VMC, OTCPK:AHCHY, NYSE:MLM, NYSE:CX, NYSE:MAS, OTCPK:ASGLY, NYSE:JHX, OTCPK:JSGRY, NYSE:OC, OTCPK:TOTDY, OTCPK:KGSPF, OTCPK:BOALF, NYSE:MDU, OTCPK:PITPF » details
Traded in other countries:XCRA.Germany, CRH.UK, CRHCF.USA,
Headquarter Location:Ireland
CRH PLC manufactures and distributes building materials products. It sells frame elements, and value-added exterior products primarily to nonresidential projects.

CRH manufactures and distributes building materials products, including the fundamentals of heavy building materials, frame elements, and value-added exterior products. The company has approximately 87,000 employees at 3,800 locations in 31 countries, with 35% exposure to residential construction, 35% to nonresidential construction, and 30% to infrastructure.

Top Ranked Articles about CRH PLC

Charles Brandes Sells Microsoft, Buys McKesson The guru's largest 4th quarter trades
Charles Brandes (Trades, Portfolio) is the chairman of Brandes Investment Partners. He started the company in 1974. He manages multiple portfolios including U.S. equity and Global Equity. During the fourth quarter the guru traded shares in the following stocks: Read more...
Crisis or Opportunity? 3 Companies in 'The Auld Sod' 'Brexit' was not a crisis. Turkey is not a crisis. When is a crisis a crisis -- and when is it an opportunity?
"Brexit" was not a crisis. Turkey is not a crisis. It could become one, although that would occur based on what is happening since the coup, not the coup itself. (More on this below.) Read more...
CRH Medical Corporation Announces Majority Purchase of Arapahoe Gastroenterology Anesthesia Associates

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 30, 2016) - CRH Medical Corporation (TSX:CRH)(NYSE MKT:CRHM) ("CRH" or the "Company"), a North American medical company that provides physicians with innovative services and products for the treatment of gastrointestinal diseases, announces that it has completed a new, accretive transaction whereby CRH has acquired 51% ownership of Arapahoe Gastroenterology Anesthesia Associates, LLC ("AGAA"). AGAA provides anesthesia services to one ambulatory surgical center in Littleton, Colorado. The transaction represents CRH's first acquisition in Colorado. AGAA is expected to generate total annual revenue of US$2.6 million. The purchase price for the transaction was funded through a combination of our syndicated credit facility with Scotiabank and U.S. Bank and cash on hand. Highlights of the transaction:

Annual AGAA total revenue estimated at US$2.6 million
Accretive to EBITDA and cash flow
Transaction is structured as a joint venture; CRH has a 51% interest
First acquisition in Colorado

Edward Wright, CEO of CRH, stated, "The physicians of AGAA are CRH O'Regan System customers. This acquisition is another example of how we are leveraging our existing relationships to create growth opportunities for our anesthesia services business. This acquisition in Colorado also continues to demonstrate our ability to expand our anesthesia services business to additional states, while still maintaining the ability to create seamless integrations onto our platform." About CRH Medical Corporation: CRH Medical Corporation is a North American company focused on providing physicians with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH acquired a full service gastroenterology anesthesia company, Gastroenterology Anesthesia Associates, LLC ("GAA"), which provides anesthesia services for patients undergoing endoscopic procedures and has complemented this acquisition with seven additional acquisitions of anesthesia companies completed during the first, third and fourth quarters of 2015, and second quarter of 2016. Anesthesia assisted endoscopies make these procedures more comfortable for patients and allow gastroenterologists to perform more procedures. CRH plans to leverage the capabilities it acquired through GAA to continue to consolidate the highly fragmented gastroenterology anesthesia provider business. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves. The Company's goal is to establish CRH as the premier provider of essential services and innovative products to gastroenterologists throughout the United States. Forward looking statements: Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "should," "plan," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Readers are also cautioned regarding statements discussing estimated revenues and future growth of the acquired business; profitability; anticipated benefits; growth strategies; anticipated trends in our industry; our future financing plans; and our anticipated needs for working capital. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such forward-looking statements include the expected future revenue, anticipated benefits of the acquisition, successful completion of additional acquisitions, increasing revenue and operating EBITDA, continued growth of our business and our ability to leverage our existing operations and capabilities. Such forward-looking statements are subject to various risks and uncertainties, including risks related to integration of AGAA, the JV structure; contractual risks related to the duration of anesthesia services agreements and the risk factors identified in CRH's filings with the Canadian and U.S. securities regulators. Although CRH believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. CRH does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.





CRH Medical Corporation
David Matousek
Director of Investor Relations
800.660.2153 x1030
[email protected]
www.crhmedcorp.com




Read more...
As Brussels Overreaches and Brits Wave Goodbye, What to Buy Now In crisis there is always opportunity, and here are 2 ways to profit from what is likely to follow
In a number of discussions with clients and colleagues, I stated my belief that Brexit would carry the day and, indeed, if I were a Brit, that's how I would have voted. Read more...
CRH Medical Announces Voting Results of Shareholders Meeting

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 17, 2016) - CRH Medical Corporation (the "Company") (TSX:CRH) (NYSE MKT:CRHM), announces the following voting results for the Company's 2016 Annual Meeting of Shareholders held yesterday (the "Meeting"). At the Meeting, the number of directors was set at five, the nominees listed in the Company's management proxy circular were elected as directors, and KPMG LLP was appointed as auditor of the Company for the coming year. A total of 35,297,102 common shares of the 71,449,648 common shares outstanding were voted at the Meeting, representing approximately 49.40% of the issued and outstanding common shares of the Company. Detailed results of the vote for the election of directors are set out below:


Nominee
Votes For
% Votes For

Votes Withheld
% Votes Withheld



Dr. Anthony Holler
26,864,354
95.80
%
1,177,267
4.20
%


Dr. David Johnson
28,003,641
99.86
%
37,980
0.14
%


Todd Patrick
26,861,242
95.79
%
1,180,379
4.21
%


Ian Webb
26,861,784
95.79
%
1,179,837
4.21
%


Edward Wright
27,895,289
99.48
%
146,332
0.52
%



In addition, KPMG LLP was appointed auditor of the Company for the upcoming year, by a show of hands. About CRH Medical Corporation: CRH Medical Corporation is a North American company focused on providing physicians with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH acquired a full service gastroenterology anesthesia company, Gastroenterology Anesthesia Associates, LLC ("GAA"), which provides anesthesia services for patients undergoing endoscopic procedures. CRH complemented five additional acquisitions of anesthesia companies during 2015 and continues to execute on its acquisition strategy in 2016. Anesthesia assisted endoscopies make these procedures more comfortable for patients and allow gastroenterologists to perform more procedures. CRH plans to leverage the capabilities it acquired through GAA to continue to consolidate the highly fragmented gastroenterology anesthesia provider business. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves. The Company's goal is to establish CRH as the premier provider of essential services and innovative products to gastroenterologists throughout the United States.





CRH Medical Corporation
David Matousek
Director of Investor Relations
800.660.2153 x1030
[email protected]
www.crhmedcorp.com




Read more...
CRH Medical Corporation Announces Majority Purchase of Community Anesthesia, PLLC

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2016) - CRH Medical Corporation (TSX:CRH)(NYSE MKT:CRHM) ("CRH" or the "Company"), a North American medical company that provides physicians with innovative services and products for the treatment of gastrointestinal diseases, announces that it has completed a new, accretive transaction whereby CRH has acquired 65% ownership of Community Anesthesia, PLLC ("Community"). Community provides anesthesia services to four ambulatory surgical centers in the Greater Boston area and this transaction represents CRH's first acquisition in Massachusetts. Community is expected to generate total annual revenue of US$8.6 million. The purchase price for the transaction was funded through a combination of our syndicated credit facility with Scotiabank and U.S. Bank and cash on hand. Highlights of the transaction:

Annual total revenue estimated at US$8.6 million
Accretive to EBITDA and cash flow
Transaction is structured as a joint venture; CRH has a 65% interest
Further expands our geographic footprint

Edward Wright, CEO of CRH, stated, "We are encouraged by our ability to continue executing our growth strategy as evidenced with this latest transaction. Expanding into Massachusetts further demonstrates our ability to grow our anesthesia services business and an acquisition of this significant size will add meaningfully to our EBITDA and cash flow." About CRH Medical Corporation: CRH Medical Corporation is a North American company focused on providing physicians with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH acquired a full service gastroenterology anesthesia company, Gastroenterology Anesthesia Associates, LLC ("GAA"), which provides anesthesia services for patients undergoing endoscopic procedures and has complemented this acquisition with five additional acquisitions of anesthesia companies completed in 2015 and a sixth transaction completed in 2016. Anesthesia assisted endoscopies make these procedures more comfortable for patients and allow gastroenterologists to perform more procedures. CRH plans to leverage the capabilities it acquired through GAA to continue to consolidate the highly fragmented gastroenterology anesthesia provider business. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves. The Company's goal is to establish CRH as the premier provider of essential services and innovative products to gastroenterologists throughout the United States. Forward looking statements: Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "should," "plan," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Readers are also cautioned regarding statements discussing estimated revenues and future growth of the acquired business; profitability; anticipated benefits; growth strategies; anticipated trends in our industry; our future financing plans; and our anticipated needs for working capital. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such forward-looking statements include the expected future revenue, anticipated benefits of the acquisition, successful completion of additional acquisitions, increasing revenue and operating EBITDA, continued growth of our business and our ability to leverage our existing operations and capabilities. Such forward-looking statements are subject to various risks and uncertainties, including risks related to integration of Community, the JV structure; contractual risks related to the duration of anesthesia services agreements and the risk factors identified in CRH's filings with the Canadian and U.S. securities regulators. Although CRH believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. CRH does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.





CRH Medical Corporation
David Matousek
Director of Investor Relations
800.660.2153 x1030
[email protected]




Read more...
CRH Increases Credit Facility to Fund Additional Growth

Scotiabank syndicates credit facility with U.S. Bank

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 15, 2016) - CRH Medical Corporation (TSX:CRH)(NYSE MKT:CRHM) ("CRH" or the "Company"), a North American medical company that provides physicians with innovative products and services for the treatment of gastrointestinal diseases, has entered into an agreement with The Bank of Nova Scotia ("Scotiabank") for a US$55M Senior Secured Revolving Syndicated Credit Facility (the "Facility"). The Facility was increased from US$33M to US$55M and now includes US Bank National Association ("U.S. Bank") as a partner to CRH and Scotiabank.
The additional credit facility will be used to fund future acquisitions. The interest for the Facility is calculated using a set formula with a base rate plus 2.5% - 3.0%, depending on the Company's total debt to EBITDA ratio. Under the Facility, using the current base rate, CRH has an expected total interest cost currently of approximately 3.50% per annum. The Facility matures on April 30, 2018 and is self-amortizing with fixed quarterly repayments of approximately 5% of the outstanding balance each quarter. "CRH has now demonstrated a series of disciplined, accretive acquisitions, which has benefited both our shareholders and our creditors. Our financial strength has allowed us to expand our access to relatively low cost, non-dilutive capital in order to maintain our pace and size of accretive acquisitions. We are pleased to have partnered and grown with Scotiabank and to have also added a new partner in U.S. Bank," stated Richard Bear, Chief Financial Officer. Key benefits of the Scotiabank/U.S. Bank credit facility

Expanded Facility provides flexibility to CRH for additional acquisitions
Maintained at an attractive interest rate, currently at approximately 3.50% per annum
Additional acquisitions likely to be immediately accretive to cash flow, EBITDA and earnings
Provides credit framework for CRH to grow to the next level of critical mass

CEO of CRH, Edward Wright added "In relatively short order we have established the support from the capital markets with the accompanying, appropriate financial tools from premier banking institutions Scotiabank and U.S. Bank to help us execute on a vision of strong growth for CRH. We continue to be in active discussions with a significant pipeline of acquisition opportunities." About CRH Medical Corporation: CRH Medical Corporation is a North American company focused on providing physicians with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH acquired a full service gastroenterology anesthesia company, Gastroenterology Anesthesia Associates, LLC ("GAA"), which provides anesthesia services for patients undergoing endoscopic procedures and has complemented this acquisition with five additional acquisitions of anesthesia companies completed in 2015 and a sixth transaction completed in 2016. Anesthesia assisted endoscopies make these procedures more comfortable for patients and allow gastroenterologists to perform more procedures. CRH plans to leverage the capabilities it acquired through GAA to continue to consolidate the highly fragmented gastroenterology anesthesia provider business. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves. The Company's goal is to establish CRH as the premier provider of essential services and innovative products to gastroenterologists throughout the United States. Cautionary Note Regarding Forward-looking statements: This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "plan," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Readers are cautioned regarding statements discussing profitability; growth strategies; anticipated trends in our industry; our future financing plans; and our anticipated needs for working capital. Forward looking statements in this press release include statements regarding potential additional acquisitions and the use of the Facility to finance such acquisitions, the Company's plan to use the Facility as a revolving credit facility and to keep cash balances low, the amount of anticipated interest rates, the Company's expectation of increasing revenue and operating EBITDA, continued growth of our business and leveraging our capabilities, and the anticipated benefits of the Facility. Actual events or results may differ materially from those discussed in forward-looking statements. There can be no assurance that the forward-looking statements currently contained in this press release will in fact occur. The Company bases its forward-looking statements on information currently available to it. The Company disclaims any intent or obligations to update or revise publicly any forward-looking statements whether as a result of new information, estimates or options, future events or results or otherwise, unless required to do so by law.
Forward-looking information reflects current expectations of management regarding future events and operating performance as of the date of this document. Such information involves significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to differ materially from the results discussed in forward-looking information, including, without limitation: our ability to identify suitable acquisition candidates and to complete such acquisitions, our need for additional financing and our estimates regarding our capital requirements, future revenues and profitability; risks related to the Company's credit facilities; risks related to adverse movements in foreign currency exchange rates; risks of fluctuating interest rates and related interest expense and the other risks described in the Company's Annual Information Form, Management's Discussion and Analysis of Financial Condition and Results of Operations; its Registration Statement on Form 40-F and other documents filed with, or furnished to, Canadian securities regulators and the Securities and Exchange Commission.





CRH Medical Corporation
David Matousek
Director of Investor Relations
800.660.2153 x1030
[email protected]
www.crhmedcorp.com




Read more...
CRH Medical Corporation to Present at the Jefferies 2016 Healthcare Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 6, 2016) - CRH Medical Corporation (TSX:CRH)(NYSE MKT:CRHM) ("CRH" or the "Company"), a North American medical company that provides physicians with innovative services and products for the treatment of gastrointestinal diseases, announces that it is scheduled to present at the upcoming Jefferies 2016 Healthcare Conference in New York. Edward Wright, CEO of CRH Medical will be presenting on Thursday June 9, 2016 at 3:30 p.m. to investors attending the conference. About CRH Medical Corporation: CRH Medical Corporation is a North American company focused on providing physicians with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH acquired a full service gastroenterology anesthesia company, Gastroenterology Anesthesia Associates, LLC ("GAA"), which provides anesthesia services for patients undergoing endoscopic procedures. CRH completed an acquisition of an anesthesia company in June 2016, and five acquisitions of anesthesia companies during the first, third and fourth quarters of 2015. Anesthesia assisted endoscopies make these procedures more comfortable for patients and allow gastroenterologists to perform more procedures. CRH plans to leverage the capabilities it acquired through GAA to continue to consolidate the highly fragmented gastroenterology anesthesia provider business. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves. The Company's goal is to establish CRH as the premier provider of essential services and innovative products to gastroenterologists throughout the United States.





CRH Medical Corporation
David Matousek
Director of Investor Relations
800.660.2153 x1030
[email protected]
www.crhmedcorp.com




Read more...
CRH Medical Corporation Announces Majority Purchase of Austin Gastroenterology Anesthesia Associates

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 2, 2016) - CRH Medical Corporation (TSX:CRH)(NYSE MKT:CRHM) ("CRH" or the "Company"), a North American medical company that provides physicians with innovative services and products for the treatment of gastrointestinal diseases, announces that it has completed a new, accretive transaction whereby CRH has acquired 51% ownership of Austin Gastroenterology Anesthesia Associates, LLC ("AGAA"). AGAA provides anesthesia services to two ambulatory surgical centers in Austin, Texas. The transaction represents CRH's first acquisition in Texas. AGAA is expected to generate total annual revenue of US$11.0 million. The purchase price for the transaction was funded through our Scotiabank credit facility and cash on hand. Highlights of the transaction:

Annual AGAA total revenue estimated at US$11.0 million
Accretive to EBITDA and cash flow
Transaction is structured as a joint venture; CRH has a 51% interest
First acquisition in Texas

Edward Wright, CEO of CRH, stated, "The physicians of AGAA have been CRH O'Regan System customers for several years, underlining the importance of the relationships we've established through the product side of our business. We continue to be very encouraged by our strategy of leveraging our existing relationships to create growth opportunities for our anesthesia services business. This acquisition in Texas continues to demonstrate our ability to expand our anesthesia services business, while still maintaining the ability to create seamless integrations onto our platform. We have existing CRH O'Regan System customers across the entire country, and we look forward to increasing the reach of our anesthesia business in a meaningful way." About CRH Medical Corporation: CRH Medical Corporation is a North American company focused on providing physicians with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH acquired a full service gastroenterology anesthesia company, Gastroenterology Anesthesia Associates, LLC ("GAA"), which provides anesthesia services for patients undergoing endoscopic procedures and has complemented this acquisition with five additional acquisitions of anesthesia companies completed during the first, third and fourth quarters of 2015. Anesthesia assisted endoscopies make these procedures more comfortable for patients and allow gastroenterologists to perform more procedures. CRH plans to leverage the capabilities it acquired through GAA to continue to consolidate the highly fragmented gastroenterology anesthesia provider business. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I - IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves. The Company's goal is to establish CRH as the premier provider of essential services and innovative products to gastroenterologists throughout the United States. Forward looking statements: Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "should," "plan," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Readers are also cautioned regarding statements discussing estimated revenues and future growth of the acquired business; profitability; anticipated benefits; growth strategies; anticipated trends in our industry; our future financing plans; and our anticipated needs for working capital. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such forward-looking statements include the expected future revenue, anticipated benefits of the acquisition, successful completion of additional acquisitions, increasing revenue and operating EBITDA, continued growth of our business and our ability to leverage our existing operations and capabilities. Such forward-looking statements are subject to various risks and uncertainties, including risks related to integration of AGAA, the JV structure; contractual risks related to the duration of anesthesia services agreements and the risk factors identified in CRH's filings with the Canadian and U.S. securities regulators. Although CRH believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. CRH does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.





CRH Medical Corporation
David Matousek
Director of Investor Relations
800.660.2153 x1030
[email protected]
www.crhmedcorp.com




Read more...

Ratios

vs
industry
vs
history
PE Ratio 21.64
CRH's PE Ratio is ranked lower than
62% of the 573 Companies
in the Global Building Materials industry.

( Industry Median: 17.00 vs. CRH: 21.64 )
Ranked among companies with meaningful PE Ratio only.
CRH' s PE Ratio Range Over the Past 10 Years
Min: 15.67  Med: 23.72 Max: 36.27
Current: 21.64
15.67
36.27
Forward PE Ratio 17.30
CRH's Forward PE Ratio is ranked lower than
51% of the 185 Companies
in the Global Building Materials industry.

( Industry Median: 16.75 vs. CRH: 17.30 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.49
CRH's PE Ratio without NRI is ranked lower than
62% of the 569 Companies
in the Global Building Materials industry.

( Industry Median: 16.94 vs. CRH: 21.49 )
Ranked among companies with meaningful PE Ratio without NRI only.
CRH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.67  Med: 23.72 Max: 36.27
Current: 21.49
15.67
36.27
Price-to-Owner-Earnings 14.88
CRH's Price-to-Owner-Earnings is ranked higher than
54% of the 338 Companies
in the Global Building Materials industry.

( Industry Median: 15.89 vs. CRH: 14.88 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CRH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.43  Med: 14.68 Max: 131.72
Current: 14.88
8.43
131.72
PB Ratio 1.93
CRH's PB Ratio is ranked lower than
62% of the 681 Companies
in the Global Building Materials industry.

( Industry Median: 1.36 vs. CRH: 1.93 )
Ranked among companies with meaningful PB Ratio only.
CRH' s PB Ratio Range Over the Past 10 Years
Min: 0.73  Med: 1.36 Max: 2.04
Current: 1.93
0.73
2.04
PS Ratio 0.99
CRH's PS Ratio is ranked higher than
55% of the 691 Companies
in the Global Building Materials industry.

( Industry Median: 1.10 vs. CRH: 0.99 )
Ranked among companies with meaningful PS Ratio only.
CRH' s PS Ratio Range Over the Past 10 Years
Min: 0.44  Med: 0.73 Max: 1.11
Current: 0.99
0.44
1.11
Price-to-Free-Cash-Flow 18.08
CRH's Price-to-Free-Cash-Flow is ranked lower than
53% of the 296 Companies
in the Global Building Materials industry.

( Industry Median: 16.43 vs. CRH: 18.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CRH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.12  Med: 21.98 Max: 31.88
Current: 18.08
8.12
31.88
Price-to-Operating-Cash-Flow 11.49
CRH's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 390 Companies
in the Global Building Materials industry.

( Industry Median: 9.95 vs. CRH: 11.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CRH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.4  Med: 11.32 Max: 16.31
Current: 11.49
5.4
16.31
EV-to-EBIT 15.87
CRH's EV-to-EBIT is ranked lower than
61% of the 743 Companies
in the Global Building Materials industry.

( Industry Median: 14.30 vs. CRH: 15.87 )
Ranked among companies with meaningful EV-to-EBIT only.
CRH' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.2  Med: 18.1 Max: 173
Current: 15.87
12.2
173
EV-to-EBITDA 10.44
CRH's EV-to-EBITDA is ranked lower than
53% of the 781 Companies
in the Global Building Materials industry.

( Industry Median: 10.13 vs. CRH: 10.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.6  Med: 10.3 Max: 22.4
Current: 10.44
6.6
22.4
PEG Ratio 2.20
CRH's PEG Ratio is ranked lower than
59% of the 307 Companies
in the Global Building Materials industry.

( Industry Median: 1.56 vs. CRH: 2.20 )
Ranked among companies with meaningful PEG Ratio only.
CRH' s PEG Ratio Range Over the Past 10 Years
Min: 2.08  Med: 2.2 Max: 2.31
Current: 2.2
2.08
2.31
Shiller PE Ratio 27.82
CRH's Shiller PE Ratio is ranked higher than
52% of the 102 Companies
in the Global Building Materials industry.

( Industry Median: 30.29 vs. CRH: 27.82 )
Ranked among companies with meaningful Shiller PE Ratio only.
CRH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 6.45  Med: 10.33 Max: 27.82
Current: 27.82
6.45
27.82
Current Ratio 1.59
CRH's Current Ratio is ranked lower than
55% of the 634 Companies
in the Global Building Materials industry.

( Industry Median: 1.70 vs. CRH: 1.59 )
Ranked among companies with meaningful Current Ratio only.
CRH' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 1.85 Max: 2.68
Current: 1.59
1.46
2.68
Quick Ratio 1.09
CRH's Quick Ratio is ranked lower than
54% of the 633 Companies
in the Global Building Materials industry.

( Industry Median: 1.16 vs. CRH: 1.09 )
Ranked among companies with meaningful Quick Ratio only.
CRH' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.33 Max: 2.22
Current: 1.09
0.93
2.22
Days Inventory 58.67
CRH's Days Inventory is ranked higher than
63% of the 650 Companies
in the Global Building Materials industry.

( Industry Median: 78.00 vs. CRH: 58.67 )
Ranked among companies with meaningful Days Inventory only.
CRH' s Days Inventory Range Over the Past 10 Years
Min: 52.83  Med: 60.91 Max: 65.37
Current: 58.67
52.83
65.37
Days Sales Outstanding 45.96
CRH's Days Sales Outstanding is ranked higher than
62% of the 502 Companies
in the Global Building Materials industry.

( Industry Median: 55.32 vs. CRH: 45.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.19  Med: 48.55 Max: 55.62
Current: 45.96
40.19
55.62
Days Payable 51.61
CRH's Days Payable is ranked lower than
59% of the 460 Companies
in the Global Building Materials industry.

( Industry Median: 60.93 vs. CRH: 51.61 )
Ranked among companies with meaningful Days Payable only.
CRH' s Days Payable Range Over the Past 10 Years
Min: 36.59  Med: 57.09 Max: 79.3
Current: 51.61
36.59
79.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.89
CRH's Dividend Yield % is ranked lower than
52% of the 785 Companies
in the Global Building Materials industry.

( Industry Median: 2.10 vs. CRH: 1.89 )
Ranked among companies with meaningful Dividend Yield % only.
CRH' s Dividend Yield % Range Over the Past 10 Years
Min: 1.21  Med: 2.65 Max: 4.94
Current: 1.89
1.21
4.94
Dividend Payout Ratio 0.42
CRH's Dividend Payout Ratio is ranked lower than
59% of the 472 Companies
in the Global Building Materials industry.

( Industry Median: 0.33 vs. CRH: 0.42 )
Ranked among companies with meaningful Dividend Payout Ratio only.
CRH' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.71 Max: 0.79
Current: 0.42
0.33
0.79
3-Year Dividend Growth Rate -0.10
CRH's 3-Year Dividend Growth Rate is ranked lower than
65% of the 334 Companies
in the Global Building Materials industry.

( Industry Median: 7.70 vs. CRH: -0.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CRH' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 46
Current: -0.1
0
46
Forward Dividend Yield % 1.91
CRH's Forward Dividend Yield % is ranked lower than
55% of the 766 Companies
in the Global Building Materials industry.

( Industry Median: 2.29 vs. CRH: 1.91 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.99
CRH's 5-Year Yield-on-Cost % is ranked lower than
58% of the 956 Companies
in the Global Building Materials industry.

( Industry Median: 2.66 vs. CRH: 1.99 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CRH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.6  Med: 2.8 Max: 5.19
Current: 1.99
0.6
5.19
3-Year Average Share Buyback Ratio -4.00
CRH's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 301 Companies
in the Global Building Materials industry.

( Industry Median: -1.00 vs. CRH: -4.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.4  Med: -2.9 Max: -0.2
Current: -4
-10.4
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 4.38
CRH's Price-to-Tangible-Book is ranked lower than
81% of the 649 Companies
in the Global Building Materials industry.

( Industry Median: 1.45 vs. CRH: 4.38 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.71  Med: 2.38 Max: 4.38
Current: 4.38
1.71
4.38
Price-to-Intrinsic-Value-Projected-FCF 1.30
CRH's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
53% of the 329 Companies
in the Global Building Materials industry.

( Industry Median: 1.21 vs. CRH: 1.30 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CRH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 0.87 Max: 1.3
Current: 1.3
0.59
1.3
Price-to-Peter-Lynch-Fair-Value 2.19
CRH's Price-to-Peter-Lynch-Fair-Value is ranked lower than
75% of the 161 Companies
in the Global Building Materials industry.

( Industry Median: 1.04 vs. CRH: 2.19 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CRH' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.73  Med: 0.93 Max: 2.19
Current: 2.19
0.73
2.19
Price-to-Graham-Number 2.05
CRH's Price-to-Graham-Number is ranked lower than
75% of the 484 Companies
in the Global Building Materials industry.

( Industry Median: 1.09 vs. CRH: 2.05 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CRH' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.18  Med: 1.55 Max: 2.39
Current: 2.05
1.18
2.39
Earnings Yield (Greenblatt) % 6.30
CRH's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 862 Companies
in the Global Building Materials industry.

( Industry Median: 6.52 vs. CRH: 6.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 5.5 Max: 8.2
Current: 6.3
0.6
8.2
Forward Rate of Return (Yacktman) % 13.19
CRH's Forward Rate of Return (Yacktman) % is ranked higher than
64% of the 388 Companies
in the Global Building Materials industry.

( Industry Median: 6.58 vs. CRH: 13.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CRH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -14.8  Med: -5 Max: 13.5
Current: 13.19
-14.8
13.5

More Statistics

Revenue (TTM) (Mil) $29,463
EPS (TTM) $ 1.60
Beta0.97
Short Percentage of Float0.00%
52-Week Range $25.82 - 38.04
Shares Outstanding (Mil)832.38

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 31,340 32,900 34,986
EPS ($) 2.12 2.43 2.61
EPS without NRI ($) 2.12 2.43 2.61
EPS Growth Rate
(Future 3Y To 5Y Estimate)
24.98%
Dividends per Share ($) 0.74 0.79 0.89
» More Articles for CRH

Headlines

Articles On GuruFocus.com
CRH Announces Any and All Cash Tender Offer by CRH America, Inc. May 02 2017 
Charles Brandes Sells Microsoft, Buys McKesson Mar 27 2017 
Crisis or Opportunity? 3 Companies in "The Auld Sod" Jul 20 2016 
CRH Medical Corporation Announces Majority Purchase of Arapahoe Gastroenterology Anesthesia Associat Jun 30 2016 
As Brussels Overreaches and Brits Wave Goodbye, What to Buy Now Jun 27 2016 
CRH Medical Announces Voting Results of Shareholders Meeting Jun 17 2016 
CRH Medical Corporation Announces Majority Purchase of Community Anesthesia, PLLC Jun 16 2016 
CRH Increases Credit Facility to Fund Additional Growth Jun 15 2016 
CRH Medical Corporation to Present at the Jefferies 2016 Healthcare Conference Jun 06 2016 
CRH Medical Corporation Announces Majority Purchase of Austin Gastroenterology Anesthesia Associates Jun 02 2016 

More From Other Websites
ETFs with exposure to CRH Plc : May 2, 2017 May 02 2017
CRH Announces Any and All Cash Tender Offer by CRH America, Inc. May 02 2017
CRH America Finance, Inc. -- Moody's upgrades CRH's issuer rating to Baa1, outlook stable May 02 2017
ETFs with exposure to CRH Plc : April 19, 2017 Apr 19 2017
CRH Plc : CRH-US: Dividend Analysis : March 13th, 2017 (record date) : By the numbers : April 4,... Apr 04 2017
CRH Plc :CRH-US: Earnings Analysis: For the six months ended December 31, 2016 : March 6, 2017 Mar 06 2017
Is Ventas, Inc. (VTR) A Good Stock To Buy? Dec 13 2016
Is Koninklijke Philips NV (ADR) (PHG) a Good Stock to Buy? Dec 13 2016
Is CBS Corporation (CBS) A Good Stock To Buy? Nov 30 2016
Pioneer Natural Resources (PXD): The Most Popular Energy Stock Among Top Hedge Funds Nov 24 2016
CRH sees big U.S. infrastructure boost regardless of Trump plans Nov 17 2016
Trump 'Stock to Watch' CRH Posts 22% Revenue Rise Nov 17 2016
Italcementi S.p.A. -- Moody's upgrades HeidelbergCement to Baa3; stable outlook Nov 10 2016
ETF’s with exposure to CRH Plc : September 21, 2016 Sep 21 2016
CRH Plc :CRH-US: Earnings Analysis: For the six months ended June 30, 2016 : August 30, 2016 Aug 30 2016
ETF’s with exposure to CRH Plc : August 25, 2016 Aug 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat